Cargando…
Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
SIMPLE SUMMARY: Medulloblastoma is the most common malignant childhood brain tumour. Under standard therapy, relapse occurs in 30% of patients and is almost universally fatal, accounting for 10% of all childhood cancer deaths. A barrier to effective medulloblastoma treatment is cellular resistance t...
Autores principales: | Taylor, Louisa, Wade, Philippa K., Johnson, James E. C., Aldighieri, Macha, Morlando, Sonia, Di Leva, Gianpiero, Kerr, Ian D., Coyle, Beth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954169/ https://www.ncbi.nlm.nih.gov/pubmed/36831428 http://dx.doi.org/10.3390/cancers15041086 |
Ejemplares similares
-
MBRS-42. YB-1 - A NOVEL THERAPEUTIC TARGET IN HIGH-RISK MEDULLOBLASTOMA?
por: Taylor, Louisa, et al.
Publicado: (2020) -
MBRS-45. TWIST1 AND ABCB1 ARE FUNCTIONAL DETERMINANTS OF METASTASIS IN MEDULLOBLASTOMA
por: Cardall, Alice, et al.
Publicado: (2020) -
3D hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome
por: Linke, Franziska, et al.
Publicado: (2020) -
MEDB-25. Do extracellular vesicles transfer a multidrug resistant phenotype via ABC transporters in medulloblastoma?
por: Wade, Philippa, et al.
Publicado: (2022) -
A role for ABCB1 in prognosis, invasion and drug resistance in ependymoma
por: Sabnis, Durgagauri H., et al.
Publicado: (2019)